as tsx cth nasdaq cyna industry pharmaceuticals founded 1984 headquarters marlborough massachusetts united states parent sunovion website http www.sunovion.com cynapsus therapeutics inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of parkinson s disease . based in toronto canada . formerly named cannasat therapeutics they changed their name to cynapsus therapeutics in 2010 . 1 in september 2016 sunovion a subsidiary of dainippon sumitomo pharma announced it would acquire cynapsus therapeutics for approximately 624 million . 2 contents 1 company overview 2 products 2.1 apl 130277 3 external links 4 references company overview edit cynapsus is a specialty pharmaceutical company developing the only oral sublingual delivery of the only approved drug apomorphine to treat the motor symptoms of parkinson s disease . over one million people in the united states and an estimated 5 million people globally suffer from parkinson s disease . parkinson s disease is a chronic and progressive neurodegenerative disease that impacts motor activity and its prevalence is increasing with the aging of the population . based on the impact registry study and the results of cynapsus global 500 neurologists survey it is estimated that between 25 percent and 50 percent of patients experience off episodes in which they have impaired movement or speaking capabilities . current medications only control the disease s symptoms and most drugs become less effective over time as the disease progresses . cynapsus lead drug candidate apl 130277 is an easy to administer fast acting and oral reformulation of an approved drug apomorphine used to rescue patients from off episodes . cynapsus is focused on rapidly maximizing the value of apl 130277 by completing pivotal studies in advance of a new drug application expected to be submitted in 2015 . cynapsus anticipates out licensing to an appropriate pharmaceutical partner before such an application is submitted . products edit apl 130277 edit apl 130277 is a reformulation of an approved parkinson s drug . apl 130277 is a novel oral formulation of an approved drug for parkinson s patients designed to deliver significant clinical benefits over the current marketed treatment . the drug will treat patients with moderate to severe pd and address a significant unmet clinical need as expressed by clinicians and patients . the drug is expected to undergo accelerated approval through 505 b 2 fda regulatory pathway with the us fda and a similar pathway with other international regulatory agencies . this well developed regulatory path could result in a new drug approval application being submitted in late 2014 or early 2015 . apl 130277 has the potential to address a significant underserved portion of 3 billion parkinson s disease market . cynapsus has entered into an agreement with adagio pharmaceuticals ltd. granting cynapsus the option to execute a proposed exclusive worldwide agreement to license all intellectual property relating to and issued from continuing development apl 130277 . external links edit official website biofinance company overview references edit http www.marketwire.com press release cannasat changes name to cynapsus therapeutics tsx venture cth 1148145.htm sunovion to acquire cynapsus for 624m gen news highlights gen . retrieved from https en.wikipedia.org w index.php title cynapsus therapeutics & oldid 737417499 categories companies listed on the toronto stock exchangepharmaceutical companies of canadacompanies based in toronto navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 2 september 2016 at 17 02 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view